$93.45
0.72% yesterday
NYSE, Nov 13, 10:00 pm CET

PerkinElmer Stock price

$93.40
+2.42 2.66% 1M
-3.31 3.42% 6M
-18.21 16.32% YTD
-26.34 22.00% 1Y
-49.63 34.70% 3Y
-38.72 29.31% 5Y
+42.76 84.44% 10Y
+71.12 319.21% 20Y
NYSE, Closing price Thu, Nov 13 2025
-0.73 0.78%

New AI Insights on PerkinElmer Insights AI Insights on PerkinElmer

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$10.7b
Enterprise Value
$13.0b
Net debt
$2.3b
Cash
$931.4m
Shares outstanding
114.0m
Valuation (TTM | estimate)
P/E
45.9 | 18.8
P/S
3.8 | 3.7
EV/Sales
4.6 | 4.5
EV/FCF
26.0
P/B
1.5
Dividends
DPS
$0.28
Yield 1Y | 5Y
0.3% | 0.2%
Growth 1Y | 5Y
0.0% | 0.0%
Payout 1Y | 3Y
12.7% | 6.9%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$2.8b | $2.9b
EBITDA
$773.8m | $867.5m
EBIT
$366.5m | $790.3m
Net Income
$237.5m | $570.9m
Free Cash Flow
$497.4m
Growth (TTM | estimate)
Revenue
3.4% | 5.4%
EBITDA
-4.2% | 2.2%
EBIT
-3.4% | 87.7%
Net Income
-6.6% | 111.1%
Free Cash Flow
-11.9%
Margin (TTM | estimate)
Gross
55.3%
EBITDA
27.5% | 29.9%
EBIT
13.0%
Net
8.4% | 19.7%
Free Cash Flow
17.7%
Financial Health
Equity Ratio
61.9%
Return on Equity
3.5%
ROCE
3.4%
ROIC
-
Debt/Equity
0.4
More
EPS
$2.1
FCF per Share
$4.4
Short interest
9.8%
Employees
11k
Rev per Employee
$250.0k
Show more

Is PerkinElmer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

PerkinElmer Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a PerkinElmer forecast:

17x Buy
65%
8x Hold
31%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a PerkinElmer forecast:

Buy
65%
Hold
31%
Sell
4%

Financial data from PerkinElmer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,813 2,813
3% 3%
100%
- Direct Costs 1,258 1,258
4% 4%
45%
1,555 1,555
3% 3%
55%
- Selling and Administrative Expenses 986 986
7% 7%
35%
- Research and Development Expense 207 207
5% 5%
7%
774 774
4% 4%
28%
- Depreciation and Amortization 407 407
5% 5%
14%
EBIT (Operating Income) EBIT 366 366
3% 3%
13%
Net Profit 237 237
7% 7%
8%

In millions USD.

Don't miss a Thing! We will send you all news about PerkinElmer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PerkinElmer Stock News

Neutral
Seeking Alpha
3 days ago
Revvity, Inc. ( RVTY ) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division Good morning, everybody, and thank you all for joining us for 8 a.m. session with Revvity.
Neutral
Business Wire
3 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., today announced the launch of new highly-characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST) as part of the Somatic Reference Samples (SRS) Initiative. The Somatic Reference Samples (SRS) Initiative is a public...
Neutral
Business Wire
3 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals' solutions for bridg...
More PerkinElmer News

Company Profile

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Head office United States
CEO Prahlad Singh
Employees 11,000
Founded 1937
Website www.revvity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today